Royalty Pharma Raises 2026 Receipts Outlook

The biopharmaceutical royalty firm lifted its full-year Portfolio Receipts guidance even as third-quarter net income fell.

Updated on Nov. 5, 2026 in Biotech

Flat-color editorial illustration of amber glass vials and oval capsules on a cream surface, conveying the pharmaceutical royalty business. — Royalty Pharma raised its 2026 Portfolio Receipts outlook to $3.5 billion to $3.55 billion after third-quarter Royalty Receipts rose 9% to $883 million. AI Illustration. Upload story photo >

Royalty Pharma raised its 2026 Portfolio Receipts outlook to $3.5 billion to $3.55 billion after reporting third-quarter Royalty Receipts up 9% to $883 million. Net income attributable to the company fell to $144.7 million from $284.2 million a year earlier.

Why it matters

The guidance raise reflects continued growth in royalty payments from several marketed drugs, which matters for investors tracking how the company's portfolio performs. The decline in net income was driven largely by a $150.4 million noncash impairment charge tied to pelacarsen, a drug whose Phase 3 trial did not meet its primary endpoint.

Third-quarter Royalty Receipts reached $883 million, up 9% from $811 million, while diluted EPS per Class A share fell to 32 cents from 66 cents. The company's full-year outlook excludes any transactions announced after Nov. 4, leaving the effect of future deals unquantified.

The players

Royalty Pharma

A company that acquires biopharmaceutical royalty interests and funds drug development in exchange for future royalty payments.

Novartis

A Swiss multinational pharmaceutical company that reported the Phase 3 Lp(a)HORIZON trial result for pelacarsen.

The details

Royalty Pharma acquires royalty interests in biopharmaceutical products and funds drug development through royalty and co-funding agreements. Growth in receipts was attributed mainly to Tremfya, Voranigo, Evrysdi and Imdelltra, while total income and other revenues rose to $690.1 million from $609.3 million.

Sept. 30, 2025: Prior-year comparison quarter for Portfolio Receipts and net income.
Sept. 30, 2026: Third-quarter period ended for reported receipts and cash position.
Nov. 4, 2026: Third-quarter results released; guidance excludes later transactions.

Royalty Model Exposure

The pelacarsen impairment shows how royalty investors carry clinical-trial risk tied to individual drugs, as the failed Lp(a)HORIZON readout forced a $150.4 million write-down in the third quarter. Royalty Pharma's broader portfolio growth in Tremfya and Evrysdi offsets that exposure but does not eliminate it.

For investors holding Royalty Pharma shares, the lower third-quarter diluted EPS and the impairment charge are the figures to weigh against the raised receipts outlook. The guidance does not include any deals announced after Nov. 4, so future portfolio additions could change the picture.

The takeaway

Investors should look past the headline net income decline and focus on whether royalty receipts keep growing as the company's drugs mature. The pelacarsen write-down is a reminder that royalty returns depend on the clinical success of the underlying drugs.